Targeting PAI-1 with inhibitors like tiplaxtinin reversed these effects, suggesting PAI-1 as a promising therapeutic target to inhibit cancer progression and disrupt the stromal collagen network conducive to metastasis [25]. Here, SERPINE1 is linked to cancer.